摘要

The advent of personalized cancer treatment resulted in the shift from the administration of cytotoxic drugs with broad activity spectrum to a targeted tumor-specific therapy. Aligned to this development, the focus of this study revolved around the application of our novel and patented microtube array membrane (MTAM) in the US National Cancer Institute (NCI) developed an HFA (hollow fiber assay) assay; hereinafter known as MTAM/HFA. Electrospun poly-L-lactic acid (PLLA) MTAM was sterilized and loaded with cell lines/patient derived tumor cells (PDTC) and subcutaneously implanted into the backs of BALB/C mice. Anticancer drugs were administered at the respective time points and the respective MTAMs were retrieved and the viability tumor cells within were quantified with the MTT assay. Results revealed that the MTAMs were excellent culture substrate for various cancer cell lines and PDTCs (patient derived tumor cells). Compared to traditional HFA systems that utilize traditional hollow fibers, MTAM/HFA revealed superior drug sensitivity for a wide range of anticancer drug classes. Additionally, the duration for each test was < 14 days; all this while capable of producing similar trend outcome to the current gold-standard xenograft models. These benefits were observed in both the in vitro and in vivo stages, making it a highly practical phenotypic-based solution that could potentially be applied in personalized medicine.
原文英語
文章編號569
期刊Materials
12
發行號4
DOIs
出版狀態已發佈 - 二月 14 2019

指紋

Assays
Screening
Membranes
Cells
Acids
Tumors
Substrates
Fibers
Pharmaceutical Preparations
Oncology
Lactic acid
Cell culture
Heterografts
Gold
Medicine
poly(lactic acid)

ASJC Scopus subject areas

  • Materials Science(all)

引用此文

Electrospun polylactic acid (PLLA) microtube array membrane (MTAM)-An advanced substrate for anticancer drug screening. / Tseng, Chia Hsuan; Huang, Wan Ting; Chew, Chee Ho; Lai, Jun Kai; Tu, Shih Hsin; Wei, Po Li; Lee, Kang Yun; Lai, Gi Ming; Chen, Chien Chung.

於: Materials, 卷 12, 編號 4, 569, 14.02.2019.

研究成果: 雜誌貢獻文章

@article{871cb6f5472647aca80ace257b21598a,
title = "Electrospun polylactic acid (PLLA) microtube array membrane (MTAM)-An advanced substrate for anticancer drug screening",
abstract = "The advent of personalized cancer treatment resulted in the shift from the administration of cytotoxic drugs with broad activity spectrum to a targeted tumor-specific therapy. Aligned to this development, the focus of this study revolved around the application of our novel and patented microtube array membrane (MTAM) in the US National Cancer Institute (NCI) developed an HFA (hollow fiber assay) assay; hereinafter known as MTAM/HFA. Electrospun poly-L-lactic acid (PLLA) MTAM was sterilized and loaded with cell lines/patient derived tumor cells (PDTC) and subcutaneously implanted into the backs of BALB/C mice. Anticancer drugs were administered at the respective time points and the respective MTAMs were retrieved and the viability tumor cells within were quantified with the MTT assay. Results revealed that the MTAMs were excellent culture substrate for various cancer cell lines and PDTCs (patient derived tumor cells). Compared to traditional HFA systems that utilize traditional hollow fibers, MTAM/HFA revealed superior drug sensitivity for a wide range of anticancer drug classes. Additionally, the duration for each test was < 14 days; all this while capable of producing similar trend outcome to the current gold-standard xenograft models. These benefits were observed in both the in vitro and in vivo stages, making it a highly practical phenotypic-based solution that could potentially be applied in personalized medicine.",
keywords = "Anticancer drug screening, Electrospinning, Hollow fiber assay (HFA), Microtube array membrane (MTAM), Personalized medicine",
author = "Tseng, {Chia Hsuan} and Huang, {Wan Ting} and Chew, {Chee Ho} and Lai, {Jun Kai} and Tu, {Shih Hsin} and Wei, {Po Li} and Lee, {Kang Yun} and Lai, {Gi Ming} and Chen, {Chien Chung}",
year = "2019",
month = "2",
day = "14",
doi = "10.3390/ma12040569",
language = "English",
volume = "12",
journal = "Materials",
issn = "1996-1944",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Electrospun polylactic acid (PLLA) microtube array membrane (MTAM)-An advanced substrate for anticancer drug screening

AU - Tseng, Chia Hsuan

AU - Huang, Wan Ting

AU - Chew, Chee Ho

AU - Lai, Jun Kai

AU - Tu, Shih Hsin

AU - Wei, Po Li

AU - Lee, Kang Yun

AU - Lai, Gi Ming

AU - Chen, Chien Chung

PY - 2019/2/14

Y1 - 2019/2/14

N2 - The advent of personalized cancer treatment resulted in the shift from the administration of cytotoxic drugs with broad activity spectrum to a targeted tumor-specific therapy. Aligned to this development, the focus of this study revolved around the application of our novel and patented microtube array membrane (MTAM) in the US National Cancer Institute (NCI) developed an HFA (hollow fiber assay) assay; hereinafter known as MTAM/HFA. Electrospun poly-L-lactic acid (PLLA) MTAM was sterilized and loaded with cell lines/patient derived tumor cells (PDTC) and subcutaneously implanted into the backs of BALB/C mice. Anticancer drugs were administered at the respective time points and the respective MTAMs were retrieved and the viability tumor cells within were quantified with the MTT assay. Results revealed that the MTAMs were excellent culture substrate for various cancer cell lines and PDTCs (patient derived tumor cells). Compared to traditional HFA systems that utilize traditional hollow fibers, MTAM/HFA revealed superior drug sensitivity for a wide range of anticancer drug classes. Additionally, the duration for each test was < 14 days; all this while capable of producing similar trend outcome to the current gold-standard xenograft models. These benefits were observed in both the in vitro and in vivo stages, making it a highly practical phenotypic-based solution that could potentially be applied in personalized medicine.

AB - The advent of personalized cancer treatment resulted in the shift from the administration of cytotoxic drugs with broad activity spectrum to a targeted tumor-specific therapy. Aligned to this development, the focus of this study revolved around the application of our novel and patented microtube array membrane (MTAM) in the US National Cancer Institute (NCI) developed an HFA (hollow fiber assay) assay; hereinafter known as MTAM/HFA. Electrospun poly-L-lactic acid (PLLA) MTAM was sterilized and loaded with cell lines/patient derived tumor cells (PDTC) and subcutaneously implanted into the backs of BALB/C mice. Anticancer drugs were administered at the respective time points and the respective MTAMs were retrieved and the viability tumor cells within were quantified with the MTT assay. Results revealed that the MTAMs were excellent culture substrate for various cancer cell lines and PDTCs (patient derived tumor cells). Compared to traditional HFA systems that utilize traditional hollow fibers, MTAM/HFA revealed superior drug sensitivity for a wide range of anticancer drug classes. Additionally, the duration for each test was < 14 days; all this while capable of producing similar trend outcome to the current gold-standard xenograft models. These benefits were observed in both the in vitro and in vivo stages, making it a highly practical phenotypic-based solution that could potentially be applied in personalized medicine.

KW - Anticancer drug screening

KW - Electrospinning

KW - Hollow fiber assay (HFA)

KW - Microtube array membrane (MTAM)

KW - Personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=85061562011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061562011&partnerID=8YFLogxK

U2 - 10.3390/ma12040569

DO - 10.3390/ma12040569

M3 - Article

VL - 12

JO - Materials

JF - Materials

SN - 1996-1944

IS - 4

M1 - 569

ER -